REGN7544 + PB
Phase 2Active 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sepsis-Induced Hypotension
Conditions
Sepsis-Induced Hypotension
Trial Timeline
May 5, 2025 → Apr 30, 2026
NCT ID
NCT06608901About REGN7544 + PB
REGN7544 + PB is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Sepsis-Induced Hypotension. The current trial status is active. This product is registered under clinical trial identifier NCT06608901. Target conditions include Sepsis-Induced Hypotension.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06608901 | Phase 2 | Active |